09 September 2009 : The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
Trial reference:
A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5 x 10^7 pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2